Latent sensitization is a rodent model of chronic pain that reproduces both its episodic nature and its sensitivity to stress. It is triggered by a wide variety of injuries ranging from injection of inflammatory agents to nerve damage. It follows a characteristic time course in which a hyperalgesic phase is followed by a phase of remission. The hyperalgesic phase lasts between a few days to several months, depending on the triggering injury. Injection of μ-opioid receptor inverse agonists (e.g., naloxone or naltrexone) during the remission phase induces reinstatement of hyperalgesia. This indicates that the remission phase does not represent a return to the normal state, but rather an altered state in which hyperalgesia is masked by constitutive activity of opioid receptors. Importantly, stress also triggers reinstatement. Here we describe in detail procedures for inducing and following latent sensitization in its different phases in rats and mice. C 2015 by John Wiley & Sons, Inc.
INTRODUCTION
Many types of chronic pain, and in particular neuropathic pain, are episodic: periods of pain are interspersed with periods of remission, which resemble the healthy state but can quickly give way to yet another bout of pain. In particular, stress is a common trigger of pain episodes in these disorders. Recently, a rodent model of chronic pain has been developed that reproduces both its episodic nature and its sensitivity to stress. It has been called latent pain sensitization (Bessiere et al., 2007; Campillo et al., 2011) or latent sensitization (Lian et al., 2010) ; here we will use the later term abbreviated to LS. Figure 9 .50.1 illustrates the following basic phases of LS:
1. Tissue injury. This leads from the normal state to a period of hyperalgesia (increased responses to noxious stimuli) or allodynia (pain-like responses to a nonnoxious stimulus). A variety of noxious stimuli can induce LS in rodent models of chronic pain, including a paw incision (Li et al., 2001; Richebe et al., 2005; Rivat et al., 2007; 2011), complete Freund's adjuvant (CFA; Corder et al., 2013) , carrageenan (Bessiere et al., 2007; Le Roy et al., 2011) , and nerve injury (Solway et al., 2011) .
2. Remission of hyperalgesia. The initial hyperalgesia eventually subsides into a period of remission. The length of the initial hyperalgesic phase depends on the injury, ranging from 7 days after paw incision (Li et al., 2001 ) to ß100 days in the cuff model of neuropathic pain (Yalcin et al., 2011) .
3. Reinstatement of hyperalgesia. However, the remission phase does not represent a return to the normal state, as the hyperalgesia can be reinstated by a variety of stimuli or pharmacological agents. The most commonly used are antagonists of the μ-opioid receptor (MOR) such as naloxone or naltrexone (NTX), which reinstate the hyperalgesia for a period of time that is consistent with the pharmacokinetic half-life of the drug (2 to 4 hr). Strictly speaking, naloxone and naltrexone are inverse agonists of the MOR (see Background Information). NTX does not produce hyperalgesia in naïve animals. Of note, reinstatement by NTX can be repeated any number of times over a period of at least 5 months Corder et al., 2013) . Other stimuli such as stress can similarly reinstate the painful state (Le Roy et al., 2011) . The Basic Protocol describes how to induce LS in mice by injecting CFA in the hind paw. The Alternate Protocol provides a similar procedure to use in rats. The Support Protocol describes the use of von Frey filaments, one of the methods most commonly used to measure hyperalgesia in the different phases of LS.
BASIC PROTOCOL

COMPLETE FREUND'S ADJUVANT-INDUCED LATENT SENSITIZATION IN MICE
LS induced by injecting CFA in the hind paw of mice is a robust, well characterized instance of this pain model, so we have chosen it as an example. This protocol can be adapted to study LS induced with other stimuli by simply changing the stimulus and paying attention to the different duration of the hyperalgesic phase. For mice, some groups have found that handling increases rather than decreases struggling, and therefore, they avoid habituation. We have included here instructions for habituation (as performed in our laboratory) in case the investigator decides to use it. Materials 6-week-old to 5-month-old female or male mice, 20 g and 24 g, respectively (e.g., C57Bl/6 J, Jax Mice, The Jackson Laboratory), five to eight mice per group per gender 5. Measure baseline paw withdrawal thresholds (PWTs) with von Frey filaments once a day for 2 to 3 days before CFA injection by gently applying the von Frey filaments, between the openings of the grid, to the soft pad of the hind paw between the tori at the base of the digits. Use the up-and-down method (see Support Protocol).
6. Avoid taking measurements while the animal is standing on its hind legs, grooming, or sleeping. If sleeping, very gently nudge the trunk with a pen. When testing multiple animals, move from animal to animal depending on the activity level.
7. Return animals to their cages and usual housing room after the measurements.
8. Clean the rack and the area below it with deionized water between experiments.
Inject CFA for the hyperalgesia phase 9. Take the final baseline measurements immediately before the CFA injection, and record them as day 0. 10. Anesthetize the animals (APPENDIX 4B; Davis, 2008) in a supine position with 1% to 2% isoflurane using the vaporizer and induction box.
11. Mix the CFA thoroughly before each injection (it tends to settle at the bottom of the bottle), and draw it directly into a 50-μl Hamilton syringe with a 30-G needle. 12. Insert the needle at an oblique angle of ß20°, at the middle of the dorsal paw, near the base of the third toe ( Fig. 9 .50.3). Slowly inject CFA over 1 to 2 sec. Hold the needle in place for 5 to 15 sec to allow pressure to dissipate, and then withdraw it gently.
13. Measure PWTs the next day and on selected subsequent days (see Support Protocol).
Do not perform PWTs daily, as this may lead to stress-induced hyperalgesia. We typically measure PWTs on days 1, 3, 5, 7, 10, 14, 21, 28 after the CFA injection. This timeline Inject naltrexone for the pain reinstatement phase 14. Measure PWTs before naltrexone is injected.
This will serve a baseline to compare responses after naltrexone injection.
15. Dissolve naltrexone in sterile phosphate-buffered saline (PBS) the same day it is used, and inject 3 mg/kg in 300 μl subcutaneously at the nape.
16. Measure PWTs intermittently, e.g., at 20, 40, 60, and 120 min, or 5, 15, 30, 45, 60, 90, 120, 180 , and 240 min, and then again at 24 hr to ensure that there is a return to baseline. 
ALTERNATE PROTOCOL
COMPLETE FREUND'S ADJUVANT-INDUCED LATENT SENSITIZATION IN RATS
The protocol in rats in basically the same as in mice. Note the different range of force of the von Frey filaments and the different needle used to inject naltrexone. If the same equipment is used for mice and rats, it is critically important to wash it thoroughly to eliminate all odor of the previous species, which can be a stressor. Habituation to handling and to the testing equipment reduces variability of the data collected in rats. Davis, 2008) and euthanizing rats (APPENDIX 4H; Donovan and Brown, 2005) Habituate rats (recommended) 1. Habituate rats to the testing apparatus for 2 days, 30 min daily (see Basic Protocol).
Materials List
Rats are housed three per cage unless they have intrathecal catheters, in which case they are housed individually.
Take baseline measurements 2. Allow the rats to acclimate in the acrylic enclosures atop the elevated grid for at least 30 min before testing.
3. Measure baseline PWTs with von Frey filaments for 2 to 3 days before the CFA injection by gently applying the von Frey filaments, between the openings of the grid, to the soft pad of the hind paw between the tori at the base of the digits. Use the up-and-down method (see Support Protocol).
4. Avoid taking measurements while the animal is standing on its hind legs, grooming or sleeping. If sleeping, very gently nudge the trunk with a pen.
5. Return animals to their cages and usual housing room after the measurements.
6. Clean the rack and the area below it with deionized water between experiments. Inject CFA for the hyperalgesia phase 7. Take the final baseline measurements just before the CFA injection, and record as day 0.
8. Anesthetize the rats (APPENDIX 4B; Davis, 2008) in the induction box with 5% isoflurane, supplied by the vaporizer.
9. Mix undiluted CFA thoroughly before each injection, and draw 50 μl directly into the 1-ml Hamilton syringe with a 25-G needle.
CFA is used undiluted (100%), and the injection volume is a critical parameter. Use 50 μl for rats.
10. Insert the needle at an oblique angle from the heel in the middle of the paw, and inject the CFA. Hold the needle in place for 15 sec to allow pressure to dissipate, and then withdrawn gently.
11. On the following day, measure PWTs and on subsequent days as appropriate. Do not perform PWTs daily as this may lead to stress-induced hyperalgesia.
We typically measure PWTs on days 1, 3, 5, 7, 14, 21, 28 Inject naltrexone for the pain reinstatement phase 12. Measure PWTs just before the naltrexone injection.
This will serve a baseline to compare responses after naltrexone injection.
13. Dissolve the naltrexone the same day in sterile saline, and subcutaneously inject 1 mg/kg in 300 μl or intrathecally inject 1 μg (2.6 nmol) in 10 μl, plus an intrathecal 10 μl flush.
14. Measure PWTs intermittently, e.g., at 15, 30, 45, 60, 90, and 120 min.
Sacrifice animals and measure endpoints 15. At the end of the experiment, euthanize the rats with an overdose (100 mg/kg) of pentobarbital (APPENDIX 4H; Donovan and Brown, 2005) .
SUPPORT PROTOCOL
UP-AND-DOWN METHOD OF von FREY MEASUREMENTS
The up-and-down method using von Frey hairs has become the most common approach to the measurement of mechanical paw hypersensitivity after tissue or nerve injury. However, several other procedures are available for applying von Frey hairs, and several other stimulus paradigms can be used, e.g., the use of an electronic von Frey apparatus (Parada et al., 2003) . In-house up-and-down scoring sheet (e.g., see Fig. 9 .50.4) 1a. For mice: For the first trial, gently apply the 3.22 (0.61 g) filament between the openings of the grid, to the soft pad of the hindpaw between the tori at the base of the digits for 3 sec.
1b. For rats: For the first trial gently apply the 4.31 (2.0 g) filament between the openings of the grid, to the soft pad of the hindpaw between the tori at the base of the digits for 4 sec. 3. Record four additional measurements after the first change in response (negative to positive or positive to negative).
Examples are mouse 1, 5, and 8 on the sample scoring sheet (Fig. 9.50.4) .
A positive response is defined as an abrupt lifting of the paw that is not due to normal walking or grooming.
Do not record a value if:
(a) the filament slips off of the paw before a withdrawal (b) the filament engages the abdomen, some other sensitive area, or the wrong area of the paw (c) the filament touches the wire mesh (d) the animal moves (walks or grooms).
In all these cases, give the animal a 30-sec break before retesting with the same fiber.
5a. For mice not responding to any filament: Assign the reaction to the 4.74 fiber, the fiber of the highest gram force, as a positive response.
See mice numbers 2 and 3 in the sample scoring sheet (Fig. 9.50.4) .
5b. For rats not responding to any filament: Assign a maximum value of 15 g.
6a.
For mice responding to all filaments: Assign animals a minimum value of 0.005 g.
For example, see mouse number 4 on the sample scoring sheet (Fig. 9 .50.4).
6b. For rats responding to all filaments:
Assign animals a minimum value of 0.5 g.
In the case of mice, another complex scenario is a positive response on the first 2 fibers. In this case, we have adapted the protocol for a total of 6 measures. This is to avoid repeated testing of a mouse that appears sensitized. See mice numbers 4, 6, and 7 in the sample scoring sheet (Fig. 9.50.4).
7. When all measurements have been taken, input the X and O values into the algorithm for the up-and-down method (Chaplan et al., 1994) . Make sure to include all preceding O values to the first response on the score sheet and in the algorithm.
COMMENTARY Background Information
A brief history of LS LS was initially found to develop in the setting of opiate-induced hyperalgesia, triggered by the repeated administration of opiates like heroin, morphine (Celerier et al., 2000; Li et al., 2001) , fentanyl (Bessiere et al., 2007; Rivat et al., 2007; Rivat et al., 2009) , and remifentanil . Opiateinduced and tissue injury-induced hyperalgesia are additive and share several characteristics: they are reinstated by naloxone , seem to involve the activation of neurokinin 1 (NK1) receptors and descending pain control pathways (Rivat et al., 2009) , and can be blocked by opioid or NMDA receptor antagonists (Rivat et al., 2007; Campillo et al., 2011; Le Roy et al., 2011) .
In neuropathic pain and other chronic pain disorders, pain episodes are often triggered by stress. LS models replicate this characteristic; forced swim stress and novel environment stress can produce reinstatement when given during the remission phase (Rivat et al., 2007) , just like opioid inverse agonists. Hyperalgesic priming (Reichling and Levine, 2009; Joseph et al., 2010 ) is a model similar to LS in that it is long lasting (>3 weeks), the original hyperalgesia can be reinstated (in this case by pronociceptive agents such as prostaglandin E2) and is increased by stress. Whereas hyperalgesic priming takes place in peripheral afferent terminals, LS seems to be mediated centrally (Solway et al., 2011; Corder et al., 2013) , although LS caused by nerve injury may be also mediated peripherally (Guan et al., 2010) . Therefore, the relationship between hyperalgesic priming and LS remains unclear.
Mechanistically, both the hyperalgesia and reinstatement phases involve activation of N-methyl-D-aspartate receptors (NMDARs; Rivat et al., 2007; Campillo et al., 2011; Corder et al., 2013) , whereas the remission phase involves activation of MORs (Corder et al., 2013) or κ-opioid receptors (KORs; Campillo et al., 2011) . Although the location of opioid receptors involved in LS include the spinal cord, it is not known whether these are in dorsal horn neurons, central terminals of primary afferent, or both. Other questions to resolve are the mechanism underlying induction and maintenance of the prolonged activation of opioid receptors during the remission phase. The most obvious mechanism is the tonic release of opioid peptides in the dorsal horn. However, recent evidence suggests that remission involves constitutive signaling of MORs in the dorsal horn that silences LS and thus maintains an analgesic state (Corder et al., 2013) .
μ-opioid receptors
MORs are members of the Class A of G protein-coupled receptors (GPCRs) that are G i/o coupled and, for the most part, inhibit their cognate second messenger signaling pathways. This results in an inhibition of adenylyl cyclase and ion channels, but activation of components of the MAP kinase cascade. As MORs bind morphine, the most clinically effective analgesic, ligand-induced signaling of MORs has been extensively studied. We know that when a MOR binds its agonist, it is phosphorylated by kinases such as GRK2/3, PKA, PKC, CaMKII, and Src, which then recruit β-arrestin 1 or 2. The receptor is then internalized, rather than degraded, through a clathrin-dependent pathway and recycled through a Rab11 pathway.
In addition to such ligand-dependent signaling, MORs may signal in the absence of agonist (constitutive activity). This ligandindependent signaling state was first described for the δ-opioid receptor by Costa and Herz (1989) and relied on a pharmacological approach to detect negative intrinsic activity of GPCRs. Using an array of inverse agonists and neutral antagonists, constitutively active MORs have also been found (Wang et al., 1994) . Unlike δ-opioid receptors, these receptors do not comprise a major proportion of the total receptor population under basal conditions (Vezzi et al., 2013) . However, withdrawal from chronic morphine increases constitutively active MORs in rodents (Wang et al., 1994; Shoblock and Maidment, 2006; Shoblock and Maidment, 2007; Wang et al., 2007; Meye et al., 2012) and enhances the aversive effect of naloxone, a MOR inverse agonist, in the morphine dependent state (Shoblock and Maidment, 2006) . LS also increases constitutively active MORs to enhance endogenous analgesia and physical dependence (Corder et al., 2013) . Our understanding of this signaling state is limited, but it was recently reported that constitutive activation of PKCα results in MOR phosphorylation at Ser 363 (Illing et al., 2014) and that constitutively active receptors are rapidly internalized through a c-Src-and β-arrestin-2-dependent mechanism (Walwyn et al., 2007; Lam et al., 2011) . As the LS model involves a substantial increase in constitutive activity of MORs, it provides a unique opportunity to study this interesting signaling state. A range of questions about the pathways and molecules that activate and maintain constitutive activity and the affected receptor populations, cell types, and downstream signaling pathways remain to be determined. We posit that there must be intrinsic mechanisms to reverse LS; otherwise, any individual exposed to a severe injury would be in a state of LS. Determination of such intrinsic mechanisms could yield clues leading to cures for chronic pain.
Inverse agonists and neutral antagonists
Constitutive activity of a receptor consists of an agonist-independent increase in signaling. Compounds that decrease this signal are called inverse agonists. There are also compounds that bind to the receptor without affecting their constitutive activity, yet they eliminate both receptor activation by agonists and the inhibitory effect of the inverse agonists; these compounds are called neutral antagonists. To establish the presence of constitutive activity, it is necessary to assess the following: (1) that an inverse agonist decreases the basal signaling of the receptor and (2) that this effect of the inverse agonist disappears in the presence of a neutral antagonist. Constitutive activity of receptors other than MORs may contribute to pain remission (e.g., cannabinoid receptors), and the study of these receptors requires the availability of appropriate inverse agonists and neutral antagonists.
Critical Parameters
Injury-induced LS is robust and easily reproducible in the laboratory. This basic protocol of CFA-induced LS can be easily adapted to study other types of chronic pain by changing the insult that triggers the hyperalgesia.
Injuries used to elicit latent sensitization
Most tissue injuries that induce persistent pain (i.e., pain that lasts several days or more) have been found to induce LS. Stimuli that have been reported to induce LS in rodents include plantar incision (Li et al., 2001; Richebe et al., 2005; Rivat et al., 2007; Campillo et al., 2011; Romero et al., 2011; Corder et al., 2013) , CFA (Solway et al., 2011; Corder et al., 2013) , carrageenan (Bessiere et al., 2007; Le Roy et al., 2011) , visceral pain (Lian et al., 2010) , and nerve injury (Solway et al., 2011) . In addition, opiate drugs like morphine, fentanyl, and remifentanil can induce LS by themselves and have synergistic effects with the injury stimuli listed above (Celerier et al., 2000; Li et al., 2001; Laulin et al., 2002; Richebe et al., 2005; Rivat et al., 2009; Campillo et al., 2011) .
The choice of the stimulus used in a particular LS study would depend largely on the questions and hypotheses being considered. The first step in such a study would be to confirm that the chosen injury produces a consistent, measurable indicator of hyperalgesia or allodynia. Not all injuries produce persistent pain, and not all forms of pain elicit measureable behavioral responses. Conversely, of particular concern are models that produce a very long-lasting period of hyperalgesia. For example, some models of peripheral neuropathic pain produce hyperalgesia lasting 80 days, as in the cuff nerve injury model (Yalcin et al., 2011) , or even longer, as in the spared nerve injury model (Decosterd and Woolf, 2000) . Therefore, to study LS related to neuropathic pain, modifications must be made to reduce the severity of the nerve injury. We recommend a modified version of the spared nerve injury model, the Cp x S x model (Shields et al., 2003; Solway et al., 2011) , in which the common peroneal and sural branches of the sciatic nerve are cut and the tibial branch is left intact. Cp x S x produced a hyperalgesic phase lasting ß28 days in mice (Solway et al., 2011) and ß35 days in rats (J.C. Marvizon, unpublished observations).
Methods for measuring hyperalgesia and allodynia
Whereas the method using von Frey filaments described here measures mechanical hypersensitivity, other methods can be substituted to measure heat or cold hypersensitivity. Thus, Solway et al. (2011) measured not only tactile hypersensitivity using von Frey filaments but also cold hypersensitivity upon topical application of a drop of acetone to the plantar paw skin. Other studies (Li et al., 2001) have measured heat hyperalgesia using paw withdrawal responses to radiant heat (Hargreaves et al., 1988) . One study on LS to visceral pain (Lian et al., 2010 ) measured referred visceral hypersensitivity in rats by applying von Frey filaments to the lumbar dermatomes.
Drug administration to trigger reinstatement
In addition to inverse agonists of MORs, antagonists of other receptors can also trigger reinstatement. For example, norbinaltorphimine, a κ-opioid receptor antagonist, produces reinstatement in LS induced by plantar incision . Similarly, antagonists of Y1 or Y2 receptors for neuropeptide Y produced reinstatement to LS induced by nerve injury (Cp x S x ) or intraplantar CFA injection (Solway et al., 2011) .
The route of drug administration is another important variable. Systemic injections of compounds that cross the blood-brain barrier can potentially affect receptors anywhere in the body. As LS seems to be partially mediated by supraspinal mechanisms (Rivat et al., 2009; De Felice et al., 2011; Le Roy et al., 2011; Taylor and Corder, 2014) , this leads to uncertainty about the site of action of the drug and the location of the receptors involved following systemic administration. To determine whether the receptors involved are located in the spinal cord, drugs can be injected intrathecally. However, the use of surgicallyimplanted, chronic intrathecal catheters could cause problems with interpretation of results, because the surgical procedure used to implant the catheter may causes an injury response leading to the development of LS. Hence, LS may be present in control animals that received a nonnoxious stimulus (for example, saline instead of CFA) due to catheter implantation surgery. To avoid this problem, we recommend that intrathecal injections be conducted using an acute percutaneous method (Hylden and Wilcox, 1980) . Alternatively, a control group of animals without intrathecal catheters could be included in the experiment. Table 9 .50.1 includes a list of potential problems and possible solutions. It is very important to establish a reliable baseline of responses before applying the injury stimulus that induces LS; otherwise, it will be difficult to determine whether the thresholds of the animals have returned to baseline. PWT values No return to baseline after injecting drug to produce reinstatement Some κ-opioid receptor antagonists have extremely slow dissociation rates, to the point of being pseudoirreversible; keep measuring responses daily to find out when they return to baseline. Injection procedure has produced an injury or sensitization; the experiment may need to be repeated with a more careful injection of drug.
Troubleshooting
Reinstatement occurs spontaneously or after saline injection
Likely, the animal has been stressed, perhaps by the animal handler during injection (quite common with new investigators), which produces strong reinstatement; provide additional training to achieve rapid, minimally stressful handling methods.
During the remission phase, responses drift up or down Animals may become habituated or sensitized if pain measures are done too frequently; allow more time (e.g., 1 week) between the pain measurements. Drugs injected to produce reinstatement may induce subtle long-term effects; careful investigation using adequate controls is merited.
9.50.12
Supplement 71 greater than baseline (indicating the presence of analgesia) have been observed, but this effects tends to be small and thus requires a carefully established and reliable baseline. For these reasons, we recommend that baseline responses be assessed over multiple days, until stable. Another confounding factor is stress, which can produce a reinstatement that is as robust as that produced by naltrexone. Indeed, the presence of humans (men in particular) can cause stress in rodents and change their behavioral responses to a noxious stimulus (Sorge et al., 2014) . Therefore, testing should be completed by the same person in each experiment. Some laboratories do not repeatedly habituate mice to the testing equipment, although this is almost always recommended in rats. Unlike rats, mice do not necessarily habituate and may become even more stressed by the handling. Figure 9 .50.5 shows the results of a representative experiment in which LS was induced by injecting CFA (50 μl subcutaneous) in the hind paw of rats, as described above. Notice the robust hypersensitivity in the ipsilateral side, which resolved after 28 days (Fig. 9.50.5A ). Responses to von Frey filaments in the contralateral side remained at baseline. On day 30, rats were injected subcutaneously with 1 mg/kg naltrexone. This resulted in reinstatement of hyperalgesia for ß1 hr in the ipsilateral side and the emergence of hyperalgesia in the contralateral side (Fig. 9.50 .5B).
Anticipated Results
Time Considerations
When used as a model of chronic pain, LS experiments last weeks and thus require maintenance of animals in a controlled environment for extended periods of time. This leads to higher animal costs and more complex institutional animal care protocols, which must be considered. However, once LS has been induced, animals require only standard care and occasional behavior measurements. With adequate planning to stagger measures, a single investigator can handle a large number of animals. However, the interval between each measurement and the time taken to test a batch of mice must be taken into consideration. The number of mice being tested in one batch cannot exceed the time interval for acquiring one set of measurements. In this case, good record keeping and animal identification methods are essential.
